Is Opentrons profitable in 2026?

Opentrons has never disclosed audited revenue or profit figures. It is privately held and last raised a small round in late 2025. No public profitability data exists as of mid-2026, and its 2021 peak valuation of $1.8B (SoftBank-led Series C, Sept 23 2021) has not been reconfirmed since.

What is Opentrons worth now compared to its 2021 peak?

Opentrons hit a $1.8B valuation on Sept 23, 2021 via a $200M Series C led by SoftBank Vision Fund 2. No confirmed primary valuation has been disclosed since; the company closed only a small raise in late 2025, well below that 2021 peak level.

Who are Opentrons' biggest competitors?

Opentrons competes with benchtop automation peers like HighRes Biosolutions, Hudson Robotics and SPT Labtech, and faces larger incumbents Hamilton Company, Tecan Group, and Beckman Coulter (Danaher) in liquid handling, though those incumbents have avoided Opentrons' lower price tier historically.

Could AI replace Opentrons' robots?

AI software cannot replace physical liquid handling, but Opentrons faces risk that orchestration layers like HighRes Cellario or NVIDIA Isaac/Cosmos (partnership announced Feb 6, 2026) could treat its hardware as a commodity execution endpoint rather than owning the intelligent workflow layer itself.

What does Opentrons actually sell?

Opentrons sells benchtop liquid-handling robots, the OT-2 (launched 2018) and its successor Flex (launched 2023), sold outright with an open API, plus consumables, software subscriptions and services. It claims over 10,000 systems deployed globally as of Jan 29, 2026.

Opentrons Labworks, Inc. is privately held, backed by SoftBank Vision Fund 2, Khosla Ventures, SOSV/HAX, Y Combinator, Lerer Hippeau, Sands Capital and Sumitomo Pharma America, which holds a board seat via Chair Myrtle Potter. No IPO has been announced as of July 2026.

United States · United States

Opentrons

Makes low-cost, open-API benchtop robots that automate liquid handling in research labs.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: NVIDIA/HighRes partnerships must show named paying customers, not just demos

The call

A company with real lab presence but a valuation that fell about 90% from its 2021 peak, now betting on an unproven AI-orchestration pivot to justify staying independent.

Opentrons sells relatively cheap robots that handle liquids in research labs and has about 10,000 of them deployed worldwide, plus it makes money selling consumables like tips to keep them running. The big lab equipment makers like Hamilton and Tecan could copy this but historically don't want to sell cheap, while new AI software from companies like HighRes and NVIDIA could turn Opentrons' robots into basic tools instead of the smart part of the operation. The one thing that matters: whether Opentrons can own the AI software layer that tells its robots what to do (and lock in pharmaceutical customers with compliance certifications) or whether it becomes just another replaceable piece of equipment that any AI software can talk to.

Why

AI pressure: HighRes Cellario and NVIDIA Isaac/Cosmos orchestration software. If lab-automation software owns the decision layer, Opentrons risks becoming a cheap execution box under someone else's brain. Could AI do the core job? Only partly.

Bigger players: Hamilton Company, Tecan Group, Beckman Coulter (Danaher). These established liquid-handling makers already sell in the same labs, just at higher price points, not yet undercutting Opentrons directly. Could a giant copy it? Probably.

What protects it. Over 10,000 machines already placed in top labs, plus consumables revenue and an open API that keeps workflows tied to its hardware.

What would change this call

Whether NVIDIA or HighRes Biosolutions name Opentrons as a paying integration partner within 12 months. Shows if Opentrons owns the AI-orchestration layer or becomes a commodity execution endpoint.
Whether Opentrons closes another funding round at or below the ~$162M late-2025 mark. Shows whether investor confidence is stabilizing or continuing to deteriorate.
Whether Opentrons announces layoffs or headcount stabilizes above 150 employees by early 2027. Shows whether the multi-year contraction from 300+ staff is ending or continuing.

Key numbers

Peaked at $1.8B valuation in Series C round (2021-09-23)
Over 10,000 robotic systems deployed globally (2026-01-29)
Small raise closed near $162M post-money (2025-12-04)

Named risks

Valuation has dropped sharply from the 2021 $1.8B peak, with only a small late-2025 raise since. Severity: high
AI orchestration partners like HighRes or NVIDIA could reduce Opentrons hardware to a commodity execution endpoint. Severity: high
New CEO's AI-orchestration pivot (formalized Jan 29, 2026) has no confirmed revenue impact yet. Severity: medium
Larger incumbents (Hamilton, Tecan, Beckman Coulter) could enter Opentrons' low-price benchtop segment. Severity: medium
No audited financials or headcount figures are publicly confirmed, obscuring true trajectory. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Hamilton Company	contesting	Avoids Opentrons' low-price tier by channel strategy, not architecture, as of 2026
Tecan Group	contesting	Competes in adjacent liquid-handling segments; no confirmed entry into Opentrons' price band
Beckman Coulter (Danaher)	contesting	Biomek line targets higher-end pharma labs, leaving Opentrons the low-cost benchtop niche
HighRes Biosolutions	gaining on	Feb 4, 2026 partnership positions HighRes Cellario as the orchestration brains, risking commoditizing Opentrons hardware

Questions people ask

Is Opentrons profitable in 2026?: Opentrons has never disclosed audited revenue or profit figures. It is privately held and last raised a small round in late 2025. No public profitability data exists as of mid-2026, and its 2021 peak valuation of $1.8B (SoftBank-led Series C, Sept 23 2021) has not been reconfirmed since.
What is Opentrons worth now compared to its 2021 peak?: Opentrons hit a $1.8B valuation on Sept 23, 2021 via a $200M Series C led by SoftBank Vision Fund 2. No confirmed primary valuation has been disclosed since; the company closed only a small raise in late 2025, well below that 2021 peak level.
Who are Opentrons' biggest competitors?: Opentrons competes with benchtop automation peers like HighRes Biosolutions, Hudson Robotics and SPT Labtech, and faces larger incumbents Hamilton Company, Tecan Group, and Beckman Coulter (Danaher) in liquid handling, though those incumbents have avoided Opentrons' lower price tier historically.
Could AI replace Opentrons' robots?: AI software cannot replace physical liquid handling, but Opentrons faces risk that orchestration layers like HighRes Cellario or NVIDIA Isaac/Cosmos (partnership announced Feb 6, 2026) could treat its hardware as a commodity execution endpoint rather than owning the intelligent workflow layer itself.
What does Opentrons actually sell?: Opentrons sells benchtop liquid-handling robots, the OT-2 (launched 2018) and its successor Flex (launched 2023), sold outright with an open API, plus consumables, software subscriptions and services. It claims over 10,000 systems deployed globally as of Jan 29, 2026.
Who owns Opentrons?: Opentrons Labworks, Inc. is privately held, backed by SoftBank Vision Fund 2, Khosla Ventures, SOSV/HAX, Y Combinator, Lerer Hippeau, Sands Capital and Sumitomo Pharma America, which holds a board seat via Chair Myrtle Potter. No IPO has been announced as of July 2026.

Timeline

2026-05-18Launched Compliance Ready Software for Flex aligned to FDA 21 CFR Part 11
2026-02-06Announced NVIDIA Isaac/Cosmos partnership for physical-AI training data from robot fleet
2026-02-04Announced HighRes strategic partnership for agent-to-agent AI lab workflows, demoed at SLAS 2026
2026-01-29James Atwood formally named CEO, succeeding founder Jon Brennan-Badal
2025-11-12Neochromosome and GlobalBio launched pre-transformed antibody libraries in neoSwitch platform
2025-04-29Launched Flex neoSwitch Workstation for automated antibody discovery
2023Launched Flex, successor to OT-2, with open API
2022-12-31NYC Pandemic Response Lab, built on Opentrons robots, shut down
2021-09-23Closed $200M Series C led by SoftBank Vision Fund 2 at $1.8B valuation
2018OT-2 liquid-handling robot launched

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.